There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Privia Health Group (PRVA – Research Report) and Nuvalent (NUVL – Research Report) with bullish sentiments.
Privia Health Group (PRVA)
In a report released today, Constantine Davides from JMP Securities reiterated a Buy rating on Privia Health Group, with a price target of $27.00. The company’s shares closed last Tuesday at $21.24.
According to TipRanks.com, Davides has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Privia Health Group with a $28.71 average price target, a 38.0% upside from current levels. In a report released yesterday, Jefferies also initiated coverage with a Buy rating on the stock with a $25.00 price target.
See the top stocks recommended by analysts >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PRVA:
